Myeloid natural killer cell leukemia resembling a variant of acute promyelocytic leukemia

We report a new case of myeloid/natural killer cell acute leukemia (myeloid/NK). Blast morphology and immunophenotype were similar to a variant of promyelocytic leukemia, resistant to ATRA (acute promyelocytic leukemia with zinc finger-RARα fusion). The karyotype was normal and cells did not present RAR-α rearrangement. Genetic studies are essential for diagnosis.

A 70-year-old woman was admitted to hospital with diffuse bone pain, fever for the previous 4 days and cutaneous purpura. Laboratory values were: WBC 187x10^9/L (98% blasts with high nuclear-cytoplasm ratio; kidney-shaped nucleus, 1-3 nucleoli and fine granular cytoplasm, 1% neutrophils and 1% lymphocytes). The hemoglobin concentration was 13.4 g/dl and the platelet count 31x10^9/L. APTT was: 33.5" (34°), INR 1.3, fibrinogen 158 mg/mL, D-dimer: 2,000-4,000 ng/mL. (N< 200). Biochemical determinations were normal, except for LDH which was 760 mg/dl. Chest X-rays and an echocardiogram were normal. Bone marrow aspirate was hypercellular, 95% cells were blasts with bilobulated nucleus and fine granules resembling a microgranular variant of acute promyelocytic leukemia (APLv) (Figure 1). Cytological reaction was moderate–weak with myeloperoxidase (MOPO) and Sudan black B (SBB) and negative with α-naphthol-acetate esterase stain. The immunophenotype of the blast population was: CD33+, CD13+, CD14-, CD45-, CD11a, CD15+ and aberrant CD66+ expression (Figure 2). Samples for cytogenetic and molecular biology studies were obtained and with the provisional diagnosis of APLv, the patient started treatment with all-trans retinoic acid (ATRA) and idarubicin (PETHEMA LAP-96 Protocol).

Conventional cytogenetics (included study from chromosome 11) and reverse transcriptase polymerase chain reaction (RT-PCR) assay (PML-RARα and RAR-α-RARα) were normal. The patient was identified as having a myeloid/natural killer cell acute leukemia and treated with idarubicin and cytosine arabinoside (PETHEMA IAM-99 for patients over 65 years old). She did not respond to two cycles of chemotherapy and died.

Myeloid/natural killer cell acute leukemia is a particular form of leukemia with cytologic features similar to microgranular acute promyelocytic variant.1,21 Previously reported cases were distinguished by their lack of expression of HLA-DR and co-expression of myeloid and natural killer cell antigens.2 Some patients may have abnormalities evolving from chromosome 17 or 11 but lack the t(15;17) and do not respond to ATRA; nevertheless by morphology and immunophenotype these cases may be classified as acute promyelocytic leukemia (M3v).2

Acute promyelocytic leukemia is characterized by a mutation that affects the retinoic acid receptor α (RARα).25 In most cases a t(15;17) (q21;q22) occurs fusing the RARα and promyelocytic leukemia genes resulting in a chimeric protein with maturation block. This alteration may be reversed by the treatment with all-trans retinoic acid.6,25 APL present variant chromosomal aberrations fusing RARα with other genes.22 The most common variant is a fusion of RARα with the promyelocyte leukemia zinc finger (PLZF) gene.6 In this variant of APL the blast cells express an aberrant CD56 marker and may present t(11;17), the variant is more often seen in old patients, is refractory to ATRA treatment and has a poor prognosis.2,4,5 Preliminary reports indicate that these patients may respond to a combination of ATRA and GSTP or to a combination of ATRA and trichostatin (an inhibitor of deacetylase activity).

In our patient cutaneous purpura and hematocrit alteration were present at diagnosis; cytology and immunophenotype resembled the APL hypogranular variant, with CD66 expression in

---

Figure 1. (A) Wright-stained myeloid/NK blasts in peripheral blood. (B) Wright-stained myeloid/NK blasts in bone marrow aspiration. Original magnification ×40.
blast cells, and the disease was resistant to ATRA. Hemostatic disorders have been described in patients with myeloid/NK leukemia although, as in our patient, are less significant than in APL.

Myeloid/NK acute leukemia response to treatment is similar to that expected in patients with the AML treated with protocol daunorubicin and cytosine arabinoside (3 and 7 days, respectively), with a median survival of 30 months. However 15% of these patients have a more aggressive progression and fail to respond to conventional induction treatment, similarly to the present case.

Patients with AML with morphologic features resembling M3 and M5v, should be analyzed by flow cytometry. The panel of monoclonal antibodies may include: HLA-DR, CD34, CD33, CD13, CD15, CD16, CD56 and CD11a antigens. Complete cytogenetic and RT-PCR assays for PML-RARα and PM zinc-finger are also needed to confirm the diagnosis in these patients.

Carmen Burgaleta, Dania de Miguel, Montserrat López Rubio, Isabel Konvik, Julio García Suárez
Service of Haematology, Príncipe de Asturias University Hospital, Department of Medicine, University of Alcalá de Henares, Madrid, Spain

Key words: myeloid/NK leukemia, APLx, flow cytometry.

Acknowledgments: Grant support from FIS 00/1138.

Correspondence: Carmen Burgaleta, MD, Ph.D., Jefe del Servicio de Hematología, Hospital Universitario Príncipe de Asturias, Carretera Alcalá Meco sh, Alcalá de Henares, Madrid, Spain. Phone: international +34 91 887 8100. Fax: International +34 91 372 1271. E-mail: carmenburgaletal@hospainsalud.es

References


